Aclidinium
A long-acting muscarinic antagonist that relaxes and widens the airways by blocking acetylcholine receptors in bronchial smooth muscle, making breathing easier. It is used twice daily as an inhaled maintenance treatment for chronic obstructive pulmonary disease (COPD) to reduce breathlessness and prevent exacerbations. It is not a rescue inhaler and should not be used for sudden episodes of breathlessness.
Masse moléculaire
484,7000 g/mol
LogP
4,70
TPSA
112,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Structure 2D
Cite this structure
Embed this structure
SMILES
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1
InChI
InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1
Molecular Formula
C26H30NO4S2+
HBD / HBA
1 / 6
Liaisons Rotatives
10
Atomes Lourds
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A long-acting muscarinic antagonist that relaxes and widens the airways by blocking acetylcholine receptors in bronchial smooth muscle, making breathing easier. It is used twice daily as an inhaled maintenance treatment for chronic obstructive pulmonary disease (COPD) to reduce breathlessness and prevent exacerbations. It is not a rescue inhaler and should not be used for sudden episodes of breathlessness.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Aclidinium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1194325. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11434515. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="aclidinium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/aclidinium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/aclidinium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/aclidinium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="aclidinium"></drugfyi-drug>